288
Participants
Start Date
July 31, 1999
Primary Completion Date
January 31, 2010
Study Completion Date
January 31, 2010
Moroctocog alfa
Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Pfizer Investigational Site, Berlin
Pfizer Investigational Site, Berlin
Pfizer Investigational Site, Potsdam
Pfizer Investigational Site, Rostock
Pfizer Investigational Site, Schwerin
Pfizer Investigational Site, Hamburg
Pfizer Investigational Site, Lübeck
Pfizer Investigational Site, Bermen
Pfizer Investigational Site, Hanover
Pfizer Investigational Site, Giessen
Pfizer Investigational Site, Bonn
Pfizer Investigational Site, Frankfurt A. M.
Pfizer Investigational Site, Frankfurt am Main
Pfizer Investigational Site, Wiesbaden
Pfizer Investigational Site, Homburg
Pfizer Investigational Site, Heidelberg
Pfizer Investigational Site, München
Pfizer Investigational Site, München
Pfizer Investigational Site, Ulm
Pfizer Investigational Site, Erlangen
Pfizer Investigational Site, Vienna
Pfizer Investigational Site, Halle
Pfizer Investigational Site, Stadtroda
Pfizer Investigational Site, Klipphausen
Pfizer Investigational Site, Leipzig
Pfizer Investigational Site, Münster
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY